| Curtis James Boyd Iii, DO | |
|
625 United Dr Ste 360, Conway, AR 72032 | |
| (501) 358-6941 | |
| (501) 358-6951 |
| Full Name | Curtis James Boyd Iii |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 8 Years |
| Location | 625 United Dr Ste 360, Conway, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346501020 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Arkansas Ob/gyn Assoc.,plc | 2668478926 | 6 |
| Western Missouri Medical Center | 2062493653 | 6 |
News Archive
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
Historically, efforts to improve end-of-life care have focused primarily on patients with cancer. But few studies have looked at the quality of end-of-life care for patients with other serious illnesses, such as lung, kidney or heart failure or dementia.
The South African Department of Health will be celebrating World Breastfeeding Week from the 1st August to 7th August 2005. World Breastfeeding Week (WBW) takes place annually from the 1st to 7th August and was created by World Alliance for Breastfeeding Action (WABA) in 1990.
Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.
› Verified 1 days ago
| Entity Name | Cooper Clinic Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154341931 PECOS PAC ID: 1153219621 Enrollment ID: O20040607000412 |
News Archive
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
Historically, efforts to improve end-of-life care have focused primarily on patients with cancer. But few studies have looked at the quality of end-of-life care for patients with other serious illnesses, such as lung, kidney or heart failure or dementia.
The South African Department of Health will be celebrating World Breastfeeding Week from the 1st August to 7th August 2005. World Breastfeeding Week (WBW) takes place annually from the 1st to 7th August and was created by World Alliance for Breastfeeding Action (WABA) in 1990.
Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.
› Verified 1 days ago
| Entity Name | Northwest Arkansas Ob/gyn Assoc.,plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053344234 PECOS PAC ID: 2668478926 Enrollment ID: O20061024000589 |
News Archive
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
Historically, efforts to improve end-of-life care have focused primarily on patients with cancer. But few studies have looked at the quality of end-of-life care for patients with other serious illnesses, such as lung, kidney or heart failure or dementia.
The South African Department of Health will be celebrating World Breastfeeding Week from the 1st August to 7th August 2005. World Breastfeeding Week (WBW) takes place annually from the 1st to 7th August and was created by World Alliance for Breastfeeding Action (WABA) in 1990.
Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.
› Verified 1 days ago
| Entity Name | Obhg Arkansas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962862920 PECOS PAC ID: 4880984558 Enrollment ID: O20160608001838 |
News Archive
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
Historically, efforts to improve end-of-life care have focused primarily on patients with cancer. But few studies have looked at the quality of end-of-life care for patients with other serious illnesses, such as lung, kidney or heart failure or dementia.
The South African Department of Health will be celebrating World Breastfeeding Week from the 1st August to 7th August 2005. World Breastfeeding Week (WBW) takes place annually from the 1st to 7th August and was created by World Alliance for Breastfeeding Action (WABA) in 1990.
Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Curtis James Boyd Iii, DO 625 United Dr Ste 360, Conway, AR 72032-7831 Ph: (501) 358-6941 | Curtis James Boyd Iii, DO 625 United Dr Ste 360, Conway, AR 72032 Ph: (501) 358-6941 |
News Archive
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
Historically, efforts to improve end-of-life care have focused primarily on patients with cancer. But few studies have looked at the quality of end-of-life care for patients with other serious illnesses, such as lung, kidney or heart failure or dementia.
The South African Department of Health will be celebrating World Breastfeeding Week from the 1st August to 7th August 2005. World Breastfeeding Week (WBW) takes place annually from the 1st to 7th August and was created by World Alliance for Breastfeeding Action (WABA) in 1990.
Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.
› Verified 1 days ago
Keitha Dewitt Holland, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2180 Ada Avenue, Suite 300, Conway, AR 72034 Phone: 501-327-6547 Fax: 501-327-3478 | |
Paul Lewis Mcchristian, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2519 College Ave, Conway, AR 72034 Phone: 501-327-6547 Fax: 501-327-9715 | |
Dr. Brandie Mcnabb Martin, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2519 College Ave, Conway, AR 72034 Phone: 501-450-3920 Fax: 501-450-7718 | |
Dr. Debra C Lawrence, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2519 College Ave, Conway, AR 72034 Phone: 501-450-3920 Fax: 501-450-7718 | |
Audrey Tobey, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 625 United Dr Ste 420, Conway, AR 72032 Phone: 501-358-6941 | |
Phillip Thomas Gullic, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2180 Ada Avenue, Suite 300, Conway, AR 72034 Phone: 501-327-6547 Fax: 501-327-9715 | |
Andrew Axley Cole, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2180 Ada Avenue, Suite 300, Conway, AR 72034 Phone: 501-327-6547 Fax: 501-327-9715 |